Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2016

View Archived Issues

Takeda and Altos Therapeutics partner to develop ATC-1906 for gastroparesis

Novartis phase I trial triggers milestone payment to MorphoSys

FPA-144 named FDA orphan for gastric/gastroesophageal junction cancer

GSK initiates phase I trial of ICOS agonist antibody GSK-3359609

Janssen Pharmaceutica patents PI3Kbeta inhibitors

Pulmocide discloses respiratory syncytial virus fusion inhibitors

Cancer Research Technology announces PARG inhibitors

Pimco 2664 presents compounds for rheumatoid arthritis

Pfizer reports AXL kinase inhibitors

GlaxoSmithKline presents KMO inhibitors

GenKyoTex divulges NADPH oxidase 1 inhibitors

EMA grants an expansion to orphan drug designation for ATIR-101

Inhibition of ATR and WDR5 shows promising activity in pancreatic ductal adenocarcinoma

New conditionally replicating adenovirus to kill tumorigenic cells

Discovery of novel potent and selective TTK inhibitor CFI-402257

AbbVie receives approval for Duodopa combination intraduodenal gel in Japan

Maruho's Hemangiol receives Japanese approval for treatment of infantile hemangioma

Simponi receives approval in Europe for treatment of polyarticular juvenile idiopathic arthritis

Praluent approved in Japan

Cinfa reports promising topline data for pegfilgrastim biosimilar

TiGenix signs agreement with Takeda for Cx-601, withdraws ChondroCelect marketing authorization

European Commission approves Ongentys in Parkinson's disease

NicOx announces agreement with GHO Capital to transfer commercial operations to new company

EMA's review of conditional MAA for masitinib to follow standard timeline

FDA clears IND for Biohaven's BHV-4157

OncoBEAM RAS CRC test available in Italy

Gemcitabine/S-1/nafamostat mesilate combination shows promise for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...